Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Primary inoperable breast cancer].

Julie Jørgensen1, Søren Cold, Claus Kamby

  • 1Hvidovre Hospital, Gastroenheden, Kirurgisk Sektion 435, Odense Universitetshospital, Onkologisk Afdeling. frk@doktor.dk

Ugeskrift for Laeger
|September 20, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer: Final Analysis of the Randomized DBCG 07-READ Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same author

Ensemble-based classification using microRNA expression identifies a breast cancer patient subgroup with an ultralow long-term risk of metastases.

Cancer medicine·2024
Same author

Response to Van Cauwenberge, Borremans, Van Houdt, et al.

Journal of the National Cancer Institute·2023
Same author

Effect of melatonin cream on acute radiation dermatitis in patients with primary breast cancer: A double-blind, randomized, placebo-controlled trial.

Journal of pineal research·2023
Same author

Response to Pederson et al. and Chlebowski et al.

Journal of the National Cancer Institute·2022
Same author

Quality-of-life outcomes following topical melatonin application against acute radiation dermatitis in patients with early breast cancer: A double-blind, randomized, placebo-controlled trial.

Journal of pineal research·2022
Same journal

[Mosaicism as a cause of Cowden syndrome].

Ugeskrift for laeger·2026
Same journal

[Thyrotoxic crisis with cardiogenic shock].

Ugeskrift for laeger·2026
Same journal

[Mindfulness-based cognitive therapy in the treatment of depression].

Ugeskrift for laeger·2026
Same journal

[Fitness].

Ugeskrift for laeger·2026
Same journal

[Risk of developing cataract related to fluoroscopy].

Ugeskrift for laeger·2026
Same journal

[Obturator hernia with small bowel ileus presenting as hip pain in an elderly woman].

Ugeskrift for laeger·2026
See all related articles

Locally advanced breast cancer (LABC) treatment involves neoadjuvant chemotherapy (NC). Predicting pathological complete response (pCR) to NC is crucial for improving survival outcomes in LABC patients.

Area of Science:

  • Oncology
  • Medical Research

Context:

  • Locally advanced breast cancer (LABC) represents a small but significant subset of breast cancer diagnoses.
  • Current standard treatment involves neoadjuvant chemotherapy (NC) prior to surgery.
  • Achieving pathological complete response (pCR) to NC is a key indicator of patient survival.

Purpose:

  • To explore strategies for improving pathological complete response (pCR) rates in patients with locally advanced breast cancer (LABC).
  • To evaluate the potential of novel biotechnological approaches in predicting treatment response to neoadjuvant chemotherapy (NC).

Summary:

  • Neoadjuvant chemotherapy (NC) regimens, including anthracyclines, are standard for LABC.
  • Addition of paclitaxel, docetaxel, and trastuzumab may enhance response rates.

Related Experiment Videos

  • Predicting treatment response through advanced biotechnological methods is an area of active investigation.

    • Impact:

    • Improved prediction of treatment response could personalize LABC therapy.
    • Enhancing pCR rates may lead to better survival outcomes for LABC patients.
    • Biotechnological advancements offer potential for more effective LABC management.